From therapeutic hypothermia towards targeted temperature management: a decade of evolution.
Anaesthesiol Intensive Ther
; 47(2): 156-61, 2015.
Article
em En
| MEDLINE
| ID: mdl-25421924
ABSTRACT
More than a decade after the first randomised controlled trials with targeted temperature management (TTM), it remains the only treatment with proven favourable effect on postanoxemic brain damage after out-of-hospital cardiac arrest. Other well-known indications include neurotrauma, subarachnoidal haemorrhage, and intracranial hypertension. When possible pitfalls are taken into consideration when implementing TTM, the side effects are manageable. After the recent TTM trials, it seems that classic TTM (32-34°C) is as effective and safe as TTM at 36°C. This supports the belief that fever prevention is one of the pivotal mechanisms that account for the success of TTM. Uncertainty remains concerning cooling method, timing, speed of cooling and rewarming. New data indicates that TTM is safe and feasible in cardiogenic shock, one of its classic contra-indications. Moreover, there are limited indications that TTM might be considered as a therapy for cardiogenic shock per se.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Choque Cardiogênico
/
Hipotermia Induzida
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Anaesthesiol Intensive Ther
Assunto da revista:
ANESTESIOLOGIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Bélgica